

Corporate Office, Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka -1207. Web: www.acmeglobal.com

## PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of **The ACME Laboratories Ltd.** in its **162**<sup>nd</sup> **Meeting** held on **Monday, 28 April 2025** at **3:30 p.m.** through Digital Platform has approved the Third Quarter (Q3) Un-Audited Financial Statements of the Company for the period ended 31 March 2025 and disclosed the following financial indicators of the Company:

(Amount in BDT)

Particulars		As at 31 March 2025		As at 30 June 2024	
i) Net Asset Value (NAV) (in million)	:	26,065.75		25,051.83	
ii) Net Asset Value Per Share (NAVPS)	:	123.18		118.39	
		From 01 July 2024 to 31 March 2025	From 01 July 2023 to 31 March 2024	From 01 January 2025 to 31 March 2025	From 01 January 2024 to 31 March 2024
iii) Net Profit After Tax (in million)	:	1,752.82	1,805.75	595.00	582.30
iv) Earnings Per Share (EPS)	:	8.28	8.53	2.81	2.75
v) Net Operating Cash Flow Per Share (NOCFPS)	:	7.79	5.77	_	_

The details of the Third Quarter (Q3) Un-Audited Financial Statements for the period ended 31 March 2025 are available in the website of the Company at www.acmeglobal.com

Dated: **Dhaka**28 April 2025

By order of the Board Sd/-**Masudur Rahman Bhuiyan, Fcs** Company Secretary